COVID-19

News

Lilly's antibody therapy cuts hospitalisation rates in COVID...

Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease.<

Digital

Deep Dive: Communications 2020

COVID-19 might have forced pharma to finally fully embrace digital comms, but it’s been a steep learning curve and expertise varies across the industry.

News

US experts stress over safety of AZ's COVID-19 vaccine

US medical experts are reportedly concerned that a neurological side effect picked up in AstraZeneca’s closely-watched COVID-19 vaccine trial could compromise the whole project, as the FDA

News

NIH hands out seven digital health contracts to fight COVID-...

The US National Institutes of Health has awarded seven contracts to companies and academic institutions to develop digital health solutions to help fight the COVID-19 pandemic.

News

Regeneron tests COVID-19 antibody therapy in UK's RECOVERY t...

Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the

News

Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-...

Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial

Lilly's antibody therapy cuts hospitalisation rates in COVID...

Deep Dive: Communications 2020

US experts stress over safety of AZ's COVID-19 vaccine

NIH hands out seven digital health contracts to fight COVID-...

Regeneron tests COVID-19 antibody therapy in UK's RECOVERY t...

Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

COVID-19

Editor's Picks